查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2007874

生物感测器诊断市场预测至2034年—按产品类型、技术、分销管道、应用、最终用户和地区分類的全球分析

Biosensor Diagnostics Market Forecasts to 2034 - Global Analysis By Product Type, Technology, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2026 年，全球生物感测器诊断市场规模将达到 286 亿美元，并在预测期内以 15.3% 的复合年增长率增长，到 2034 年将达到 894 亿美元。

生物感测器诊断是指将酵素、抗体、核酸或活细胞等生物辨识元件与物理化学转换器结合，用于检测和定量临床、环境、食品安全和研究领域中的生物分析物的分析仪器。这些仪器基于电化学、光学、压电或热检测原理运行，并产生与目标分析物浓度成正比的讯号。典型应用包括连续血糖监测、感染疾病检测、心臟生物标记定量以及即时检测 (PoC) 和检查室环境中的癌症诊断筛检。

即时诊断的需求

随着全球医疗系统优先发展分散式检查能力，以减少检查室处理延迟并实现即时临床决策，即时诊断的需求成为市场的主要驱动力。基于生物感测器的快速诊断设备在检测血糖值、肌钙蛋白和感染疾病病原体方面，已展现出与检查室分析仪相当的临床准确性。需要持续监测的慢性疾病（尤其是糖尿病）的日益普遍，为服务居家照护和门诊机构的生物感测器製造商带来了来自耗材和设备更换的可持续收入来源。

感测器精度和校准限值

感测器精度和校准方面的限制仍然是持续存在的技术难题，尤其是在可连续佩戴的生物感测器中，这些感测器需要在多种生理条件下运行，包括出汗、体温波动和用户移动等因素的影响。长时间配戴会导致电化学感测器漂移，从而降低临床可靠性，需要频繁重新校准和更换，增加使用者负担。监管机构要求证明其临床等效性与检查室参考方法相符，这需要进行严格的检验测试，从而推高研发成本并延长产品上市时间。

穿戴式连续监测市场

穿戴式连续监测技术蕴藏着巨大的成长潜力，微型生物感测器与消费级穿戴式平台的融合，在传统临床诊断之外，创造了一个价值数十亿美元的潜在市场。连续血糖监测的应用范围正从第1型糖尿病扩展到第2型糖尿病，甚至包括糖尿病前期健康管理。基于汗液的电化学生物感测器能够进行非侵入性的电解质和代谢物监测，目前正进入商业化开发阶段，其在运动表现和远端患者监护等领域的应用吸引了许多投资者和战略合作伙伴的浓厚兴趣。

来自仿冒品产品的竞争

假冒仿冒品生物感测器产品的氾滥对市场健康构成重大威胁。发展中国家不受监管的製造商以远低于市价的价格供应检验的诊断设备，严重损害了临床对生物感测器诊断的信任。主要新兴市场经济体监管执法能力的不足，使得不合格产品得以透过医院和药房的通路流通。低品质产品的价格竞争压力正在挤压高端生物感测器製造商的利润空间，使其难以证明自身技术具有显着优势。

新冠疫情的影响：

新冠疫情彻底改变了生物感测器诊断市场，对快速抗原和抗体检测生物感测器设备的需求空前高涨，推动了产能提升，并为监管机构的紧急使用授权树立了先例。疫情期间对即时检测基础设施的投资已深深融入医疗保健体系。即使在后疫情时代，呼吸道病原体生物感测器和穿戴式病患监测解决方案的应用，也持续受益于疫情期间建立的製度化远距医疗模式。

在预测期内，奈米机械生物感测器领域预计将成为最大的细分市场。

由于奈米机械生物感测器具有卓越的灵敏度，预计在预测期内将占据最大的市场份额。这种灵敏度使其能够检测癌症生物标记和病原体诊断应用中至关重要的超低浓度阈值物。奈米机械悬臂樑和共振器平台能够实现飞摩尔级的侦测能力，这是传统电化学设计无法达到的。奈米机械原理与下一代临床实验室设备和研究诊断仪器的日益整合，正推动学术机构和临床检查室的持续采购。

预计在预测期内，基于酵素的生物感测器领域将呈现最高的复合年增长率。

在预测期内，酶基生物感测器领域预计将呈现最高的增长率，这主要得益于连续血糖监测设备的日益普及、照护现场中乳酸和尿酸检测的广泛应用，以及用于环境毒素检测的新型酶生物感测器的开发。酵素固定化技术的进步正在延长感测器的运作并降低性能变异性。领先的诊断设备製造商正在加大对酵素生物感测器耗材平台的投资，这些平台支援基于订阅的经营模式，从而产生持续的收入。

市占率最大的地区：

在整个预测期内，北美预计将保持最大的市场份额。这主要归功于糖尿病的高发生率推动了持续血糖监测的普及，完善的家庭诊断保险报销体系，以及开发尖端生物感测器技术的成熟基础设施。美国食品药物管理局（FDA）制定的医疗设备监管路径正在加速生物感测器的商业化进程。雅培和德康等公司透过不断改进产品和扩展其穿戴式诊断平台产品组合，保持其市场主导地位。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于印度和中国糖尿病患者数量的快速增长、对照护现场诊断基础设施投资的增加以及政府支持国内医疗设备製造的各项计划。中国国家药品监督管理局正在简化体外诊断医疗设备的核准流程，加速生物感测器产品的市场推广。区域製造成本优势正推动生物感测器产能从西方市场转移。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 应客户要求，我们提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需进行可行性检查）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章执行摘要

  • 市场概览及主要亮点
  • 驱动因素、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章 全球生物感测器诊断市场：依产品类型划分

  • 电化学生物感测器
  • 光学生物感测器
  • 压电感测器
  • 热生物感测器
  • 奈米机械生物感测器
  • 穿戴式生物感测器
  • 其他产品类型

第六章 全球生物感测器诊断市场：依技术划分

  • 基于酵素的生物感测器
  • 免疫感测器
  • DNA生物感测器
  • 奈米生物感测器
  • 微流体生物感测器
  • 晶片实验室技术

第七章 全球生物感测器诊断市场：按分销管道划分

  • 直销
  • 线上销售
  • 药局
  • 销售代理
  • 医疗服务提供方
  • 第三方供应商

第八章 全球生物感测器诊断市场：按应用划分

  • 血糖监测
  • 感染疾病检测
  • 心臟生物标记检测
  • 癌症诊断
  • 胆固醇检测
  • 药物发现与开发
  • 其他用途

第九章 全球生物感测器诊断市场：依最终用户划分

  • 医院
  • 诊断检查室
  • 居家医疗环境
  • 研究机构
  • 製药公司
  • 生技公司
  • 其他最终用户

第十章 全球生物感测器诊断市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十一章 策略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十二章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟和合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十三章：公司简介

  • Abbott Laboratories
  • Roche Diagnostics
  • Siemens Healthineers
  • Medtronic plc
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • Nova Biomedical
  • AgaMatrix Inc.
  • Dexcom, Inc.
  • Ascensia Diabetes Care
  • Senseonics Holdings, Inc.
  • EKF Diagnostics Holdings plc
  • Universal Biosensors, Inc.
  • PerkinElmer, Inc.
  • Honeywell International Inc.
  • GE Healthcare
  • Nipro Corporation
Product Code: SMRC34764

According to Stratistics MRC, the Global Biosensor Diagnostics Market is accounted for $28.6 billion in 2026 and is expected to reach $89.4 billion by 2034 growing at a CAGR of 15.3% during the forecast period. Biosensor diagnostics refer to analytical devices that combine a biological recognition element including enzymes, antibodies, nucleic acids, or whole cells with a physicochemical transducer to detect and quantify biological analytes in clinical, environmental, food safety, and research contexts. They operate through electrochemical, optical, piezoelectric, or thermal detection principles to generate signals proportional to target analyte concentration. Common applications include continuous glucose monitoring, infectious disease detection, cardiac biomarker quantification, and cancer diagnostic screening in point-of-care and laboratory settings.

Market Dynamics:

Driver:

Point-of-Care Diagnostics Demand

Point-of-care diagnostics demand is the primary market driver as healthcare systems globally prioritize decentralized testing capabilities that reduce laboratory processing delays and enable immediate clinical decision-making. Biosensor-based rapid test devices have demonstrated clinical accuracy comparable to laboratory analyzers for glucose, troponin, and infectious pathogen detection. Growing prevalence of chronic diseases requiring continuous monitoring, particularly diabetes, is generating sustained consumable and device replacement revenue streams for biosensor manufacturers serving home care and ambulatory settings.

Restraint:

Sensor Accuracy and Calibration Limitations

Sensor accuracy and calibration limitations represent an ongoing technical restraint, particularly for continuous wearable biosensors operating across varying physiological conditions including perspiration, body temperature fluctuations, and user movement artifacts. Electrochemical sensor drift over extended wear periods reduces clinical-grade reliability, requiring frequent recalibration or replacement that increases user burden. Regulatory requirements for demonstrating clinical equivalence to laboratory reference methods impose demanding validation study requirements that elevate development costs and extend time-to-market timelines.

Opportunity:

Wearable Continuous Monitoring Markets

Wearable continuous monitoring represents an expansive growth opportunity as miniaturized biosensor integration with consumer wearable platforms creates multi-billion-dollar addressable markets beyond traditional clinical diagnostics. Continuous glucose monitor adoption is expanding from Type 1 diabetes into Type 2 and pre-diabetes wellness monitoring. Sweat-based electrochemical biosensors capable of non-invasive electrolyte and metabolite monitoring are entering commercial development, with sports performance and remote patient monitoring applications generating substantial investor and strategic partner interest.

Threat:

Counterfeit and Low-quality Competition

Counterfeit and low-quality biosensor product proliferation poses a significant market integrity threat, as unregulated manufacturers in developing markets supply non-validated diagnostic devices at substantially lower price points, undermining clinical confidence in biosensor diagnostics broadly. Regulatory enforcement capacity limitations in major emerging market economies allow substandard devices to circulate across hospital and pharmacy distribution channels. Competitive pricing pressure from low-quality products erodes premium biosensor manufacturer margins and complicates evidence-based technology differentiation arguments.

Covid-19 Impact:

COVID-19 transformed the biosensor diagnostics market by generating unprecedented demand for rapid antigen and antibody detection biosensor devices, driving manufacturing capacity expansion and regulatory emergency use authorization precedents. Pandemic-era investments in point-of-care testing infrastructure have persisted structurally in healthcare systems. Post-pandemic, respiratory pathogen biosensor applications and wearable patient monitoring solutions continue benefiting from institutionalized remote care models established during the emergency period.

The nanomechanical biosensors segment is expected to be the largest during the forecast period

The nanomechanical biosensors segment is expected to account for the largest market share during the forecast period, due to superior sensitivity enabling ultra-low analyte detection thresholds critical for cancer biomarker and pathogen diagnostics applications. Nanomechanical cantilever and resonator platforms demonstrate femtomolar detection capabilities unachievable by conventional electrochemical designs. Growing integration of nanomechanical principles into next-generation laboratory analyzers and research diagnostic instruments is driving sustained academic and clinical laboratory procurement.

The enzyme-based biosensors segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the enzyme-based biosensors segment is predicted to witness the highest growth rate, driven by expanding continuous glucose monitoring device adoption, growing point-of-care lactate and uric acid testing applications, and novel enzyme biosensor development for environmental toxin detection. Enzyme immobilization technology improvements are extending sensor operational lifespans and reducing performance variability. Major diagnostic manufacturers are intensifying investment in enzyme biosensor consumable platforms supporting recurring revenue subscription business models.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to high diabetes prevalence driving continuous glucose monitor adoption, strong reimbursement coverage for home diagnostics, and leading biosensor technology development infrastructure. The U.S. FDA's established medical device regulatory pathway facilitates biosensor commercialization timelines. Companies including Abbott Laboratories and Dexcom, Inc. maintain dominant market positions through continuous product iteration and expanding wearable diagnostic platform portfolios.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding diabetic patient populations in India and China, growing point-of-care diagnostic infrastructure investment, and government programs supporting domestic medical device manufacturing. China's National Medical Products Administration has streamlined in-vitro diagnostic device approval procedures, accelerating biosensor product launches. Regional manufacturing cost advantages are attracting biosensor production capacity relocations from Western markets.

Key players in the market

Some of the key players in Biosensor Diagnostics Market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Medtronic plc, Danaher Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Nova Biomedical, AgaMatrix Inc., Dexcom, Inc., Ascensia Diabetes Care, Senseonics Holdings, Inc., EKF Diagnostics Holdings plc, Universal Biosensors, Inc., PerkinElmer, Inc., Honeywell International Inc., GE Healthcare, and Nipro Corporation.

Key Developments:

In March 2026, Siemens Healthineers announced a strategic partnership to integrate AI-driven biosensor diagnostic data analytics into hospital clinical decision support workflow platforms.

In February 2026, Dexcom, Inc. received FDA clearance for its over-the-counter continuous glucose monitoring biosensor targeting non-insulin-dependent diabetes and wellness monitoring segments.

In October 2025, Senseonics Holdings, Inc. initiated commercialization of its 365-day implantable glucose biosensor in European markets following CE mark approval for extended wear.

Product Types Covered:

  • Electrochemical Biosensors
  • Optical Biosensors
  • Piezoelectric Biosensors
  • Thermal Biosensors
  • Nanomechanical Biosensors
  • Wearable Biosensors
  • Other Product Types

Technologies Covered:

  • Enzyme-based Biosensors
  • Immunosensors
  • DNA Biosensors
  • Nano-biosensors
  • Microfluidic Biosensors
  • Lab-on-a-chip Technologies

Distribution Channels Covered:

  • Direct Sales
  • Online Sales
  • Pharmacies
  • Distributors
  • Healthcare Providers
  • Third-party Vendors

Applications Covered:

  • Glucose Monitoring
  • Infectious Disease Detection
  • Cardiac Biomarker Detection
  • Cancer Diagnostics
  • Cholesterol Testing
  • Drug Discovery & Development
  • Other Applications

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Home Care Settings
  • Research Institutes
  • Pharmaceutical Companies
  • Biotechnology Firms
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Morocco
      • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Biosensor Diagnostics Market, By Product Type

  • 5.1 Electrochemical Biosensors
  • 5.2 Optical Biosensors
  • 5.3 Piezoelectric Biosensors
  • 5.4 Thermal Biosensors
  • 5.5 Nanomechanical Biosensors
  • 5.6 Wearable Biosensors
  • 5.7 Other Product Types

6 Global Biosensor Diagnostics Market, By Technology

  • 6.1 Enzyme-based Biosensors
  • 6.2 Immunosensors
  • 6.3 DNA Biosensors
  • 6.4 Nano-biosensors
  • 6.5 Microfluidic Biosensors
  • 6.6 Lab-on-a-chip Technologies

7 Global Biosensor Diagnostics Market, By Distribution Channel

  • 7.1 Direct Sales
  • 7.2 Online Sales
  • 7.3 Pharmacies
  • 7.4 Distributors
  • 7.5 Healthcare Providers
  • 7.6 Third-party Vendors

8 Global Biosensor Diagnostics Market, By Application

  • 8.1 Glucose Monitoring
  • 8.2 Infectious Disease Detection
  • 8.3 Cardiac Biomarker Detection
  • 8.4 Cancer Diagnostics
  • 8.5 Cholesterol Testing
  • 8.6 Drug Discovery & Development
  • 8.7 Other Applications

9 Global Biosensor Diagnostics Market, By End User

  • 9.1 Hospitals
  • 9.2 Diagnostic Laboratories
  • 9.3 Home Care Settings
  • 9.4 Research Institutes
  • 9.5 Pharmaceutical Companies
  • 9.6 Biotechnology Firms
  • 9.7 Other End Users

10 Global Biosensor Diagnostics Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Abbott Laboratories
  • 13.2 Roche Diagnostics
  • 13.3 Siemens Healthineers
  • 13.4 Medtronic plc
  • 13.5 Danaher Corporation
  • 13.6 Thermo Fisher Scientific Inc.
  • 13.7 Bio-Rad Laboratories, Inc.
  • 13.8 Nova Biomedical
  • 13.9 AgaMatrix Inc.
  • 13.10 Dexcom, Inc.
  • 13.11 Ascensia Diabetes Care
  • 13.12 Senseonics Holdings, Inc.
  • 13.13 EKF Diagnostics Holdings plc
  • 13.14 Universal Biosensors, Inc.
  • 13.15 PerkinElmer, Inc.
  • 13.16 Honeywell International Inc.
  • 13.17 GE Healthcare
  • 13.18 Nipro Corporation

List of Tables

  • Table 1 Global Biosensor Diagnostics Market Outlook, By Region (2023-2034)($MN)
  • Table 2 Global Biosensor Diagnostics Market Outlook, By Product Type (2023-2034)($MN)
  • Table 3 Global Biosensor Diagnostics Market Outlook, By Electrochemical Biosensors (2023-2034)($MN)
  • Table 4 Global Biosensor Diagnostics Market Outlook, By Optical Biosensors (2023-2034)($MN)
  • Table 5 Global Biosensor Diagnostics Market Outlook, By Piezoelectric Biosensors (2023-2034)($MN)
  • Table 6 Global Biosensor Diagnostics Market Outlook, By Thermal Biosensors (2023-2034)($MN)
  • Table 7 Global Biosensor Diagnostics Market Outlook, By Nanomechanical Biosensors (2023-2034)($MN)
  • Table 8 Global Biosensor Diagnostics Market Outlook, By Wearable Biosensors (2023-2034)($MN)
  • Table 9 Global Biosensor Diagnostics Market Outlook, By Other Product Types (2023-2034)($MN)
  • Table 10 Global Biosensor Diagnostics Market Outlook, By Distribution Channel (2023-2034)($MN)
  • Table 11 Global Biosensor Diagnostics Market Outlook, By Direct Sales (2023-2034)($MN)
  • Table 12 Global Biosensor Diagnostics Market Outlook, By Online Sales (2023-2034)($MN)
  • Table 13 Global Biosensor Diagnostics Market Outlook, By Pharmacies (2023-2034)($MN)
  • Table 14 Global Biosensor Diagnostics Market Outlook, By Distributors (2023-2034)($MN)
  • Table 15 Global Biosensor Diagnostics Market Outlook, By Healthcare Providers (2023-2034)($MN)
  • Table 16 Global Biosensor Diagnostics Market Outlook, By Third-party Vendors (2023-2034)($MN)
  • Table 17 Global Biosensor Diagnostics Market Outlook, By Other Distribution Channels (2023-2034)($MN)
  • Table 18 Global Biosensor Diagnostics Market Outlook, By Technology (2023-2034)($MN)
  • Table 19 Global Biosensor Diagnostics Market Outlook, By Enzyme-based Biosensors (2023-2034)($MN)
  • Table 20 Global Biosensor Diagnostics Market Outlook, By Immunosensors (2023-2034)($MN)
  • Table 21 Global Biosensor Diagnostics Market Outlook, By DNA Biosensors (2023-2034)($MN)
  • Table 22 Global Biosensor Diagnostics Market Outlook, By Nano-biosensors (2023-2034)($MN)
  • Table 23 Global Biosensor Diagnostics Market Outlook, By Microfluidic Biosensors (2023-2034)($MN)
  • Table 24 Global Biosensor Diagnostics Market Outlook, By Lab-on-a-chip Technologies (2023-2034)($MN)
  • Table 25 Global Biosensor Diagnostics Market Outlook, By Other Technologies (2023-2034)($MN)
  • Table 26 Global Biosensor Diagnostics Market Outlook, By Application (2023-2034)($MN)
  • Table 27 Global Biosensor Diagnostics Market Outlook, By Glucose Monitoring (2023-2034)($MN)
  • Table 28 Global Biosensor Diagnostics Market Outlook, By Infectious Disease Detection (2023-2034)($MN)
  • Table 29 Global Biosensor Diagnostics Market Outlook, By Cardiac Biomarker Detection (2023-2034)($MN)
  • Table 30 Global Biosensor Diagnostics Market Outlook, By Cancer Diagnostics (2023-2034)($MN)
  • Table 31 Global Biosensor Diagnostics Market Outlook, By Cholesterol Testing (2023-2034)($MN)
  • Table 32 Global Biosensor Diagnostics Market Outlook, By Drug Discovery & Development (2023-2034)($MN)
  • Table 33 Global Biosensor Diagnostics Market Outlook, By Other Applications (2023-2034)($MN)
  • Table 34 Global Biosensor Diagnostics Market Outlook, By End User (2023-2034)($MN)
  • Table 35 Global Biosensor Diagnostics Market Outlook, By Hospitals (2023-2034)($MN)
  • Table 36 Global Biosensor Diagnostics Market Outlook, By Diagnostic Laboratories (2023-2034)($MN)
  • Table 37 Global Biosensor Diagnostics Market Outlook, By Home Care Settings (2023-2034)($MN)
  • Table 38 Global Biosensor Diagnostics Market Outlook, By Research Institutes (2023-2034)($MN)
  • Table 39 Global Biosensor Diagnostics Market Outlook, By Pharmaceutical Companies (2023-2034)($MN)
  • Table 40 Global Biosensor Diagnostics Market Outlook, By Biotechnology Firms (2023-2034)($MN)
  • Table 41 Global Biosensor Diagnostics Market Outlook, By Other End Users (2023-2034)($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.